Skip to main content
Clinical Trials/NCT04776161
NCT04776161CompletedNot Applicable

Using Cues and Rewards in Patients With Arthritis and Rheumatic Disease

Brigham and Women's Hospital1 site in 1 country62 target enrollmentStarted: August 2, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
62
Locations
1
Primary Endpoint
Rate of Medication Adherence

Study Overview

Brief Summary

Non-adherence to evidence-based prescription medications results in preventable morbidity and mortality for middle-aged and older adults. Taking medications intended for daily use, like those to prevent or treat chronic conditions, is a repetitive action that has great similarity with other behaviors that must be performed consistently, such as regular exercise, healthy eating, and hand washing. In these cases, people who act consistently do so out of habit. The "repetition-cue-reward" model proposes that habit formation has three central components: behavioral repetition, associated context cues, and rewards. This model has obvious applicability to the daily repetitive activity of medication-taking but has not been tested for this behavior nor adapted as an intervention for patients in real-world care settings.

The goal of this pilot study is to evaluate the feasibility and effectiveness of using the repetition-cue-reward model of healthy habit formation to improve medication adherence in patients with arthritis and other rheumatic diseases.

Detailed Description

Non-adherence to evidence-based prescription medications results in preventable morbidity and mortality for middle-aged and older adults. Taking medications intended for daily use, like those to prevent or treat chronic conditions, is a repetitive action that has great similarity with other behaviors that must be performed consistently, such as regular exercise, healthy eating, and hand washing. In these cases, people who act consistently do so out of habit. The "repetition-cue-reward" model proposes that habit formation has three central components: behavioral repetition, associated context cues, and rewards. This model has obvious applicability to the daily repetitive activity of medication-taking but has not been tested for this behavior nor adapted as an intervention for patients in real-world care settings.

The goal of this pilot study is to evaluate the feasibility and effectiveness of using the repetition-cue-reward model of healthy habit formation to improve medication adherence in patients with arthritis and other rheumatic diseases.

This pilot study will be a 3-arm parallel randomized pragmatic trial comparing medication adherence for adults over 18 years old with arthritis, lupus, or gout who are prescribed 1-3 daily oral medications for this disease. Participants will be randomized to one of three arms for the duration of the study period. Patients in the first intervention arm will choose an event-based cue and receive daily reminder text messages reminding them of their cue. Patients in the second intervention arm will start by establishing their cue and having the donation made, but only those who show no improvement in adherence after 6 weeks will start receiving the text messages. In both interventions arms, a donation will be made to a local charity every time they take their medication. Patients in the control arm will not receive any intervention (but will receive pill bottles to monitor their adherence). Our outcomes of interest will be medication adherence, as measured by electronic pill bottles.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Health Services Research
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •English-speaking patients
  • •receiving their care at a Brigham and Women's Hospital-affiliated rheumatology practice
  • •>=18 years of age
  • •with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or gout
  • •prescribed >=1 oral medication for this disease for >=4 months.
  • •for patients with gout, had a uric acid level checked in the prior 18 months and the most recent level is >
  • •for patients with SLE, their most recent c-reactive protein level collected in the past 18 months must be >
  • •currently have a smartphone with a data plan or WiFi at home
  • •willing and able to set up the platform and adhere to study procedures
  • •either not currently using a pillbox or willing to use electronic pill bottles (EDMs) for diabetes medications for the duration of the study

Exclusion Criteria

  • •Pregnant women
  • •Incarcerated individuals

Arms & Interventions

Control

No Intervention

Patients in the control arm will not receive any intervention (but will receive electronic pill bottles to monitor their adherence).

Cue-Reward Intervention

Experimental

Patients in this intervention arm will choose an event-based cue and receive reminder text messages reminding them of their cue. Additionally, a donation will be made to a local charity every time they take their medication.

Intervention: Cue-Reward Intervention (Behavioral)

Cue-Reward Intervention with possible intensification.

Experimental

Patients in this intervention arm will choose an event-based cue. Additionally, a donation will be made to a local charity every time they take their medication. Those who show no improvement in adherence after 6 weeks will start receiving reminder text messages reminding them of their cue.

Intervention: Cue-Reward Intervention with possible intensification (Behavioral)

Outcomes

Primary Outcomes

Rate of Medication Adherence

Time Frame: 18 weeks

Medication adherence will be measured as the percentage of times a patient opened the electronic pill bottle out of the number of doses prescribed for each bottle in each day, averaged across the study medications and over follow-up.

Secondary Outcomes

  • Change in Uric Acid Level From Baseline(18 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Candace Hillary Feldman, MD

Assistant Professor

Brigham and Women's Hospital

Study Sites (1)

Loading locations...

Similar Trials